Croda Pharma: The future of novel excipients
Super Refined™ pharmaceutical excipients
The importance of excipients
Formulation development has been emphasized greatly in recent years, whether that be for targeting delivery of the drug, aesthetics of the final formulation, or shelf life of the final drug product. Some excipients play a simple role in drug formulations while others require an excipient with different properties to perform their job properly. Frequent concerns such as drug stabilisation, surface adsorption, or agglomeration are found throughout the drug development process, especially within biopharma, which reinforces the need to utilise novel and highly functional excipients. It is crucial that the right excipient is adopted to assist in preventing these common issues from occurring. The current palette of excipients has its limitations and novel excipients which aid in the delivery of these new therapeutic agents must be introduced.
Developing new therapeutics using biopharmaceuticals
Truly novel chemical entities that have been designed and manufactured as pharmaceutical excipients are exceptionally rare. Recent examples have incurred large development costs, not least in the demonstration of patient safety, and have been generally underutilised by the pharmaceutical industry. Why would a scientist formulate with a novel excipient knowing the regulatory scrutiny of the marketing authorisation dossier may trigger additional questions and delays when using a traditional excipient which would not incur such questions … even if it did not perform as well? This is yet another example of the challenge in developing new therapeutics, especially using biopharmaceuticals (“big molecules”).
Dr Iain Moore, Global Head of Quality Assurance, Croda Pharma
Dr. Moore and Croda Pharma recognise the difficulties when using and developing novel excipients and the barriers all parties face. Excipient suppliers, excipient users, and authorities can collaborate effectively to bring new novel excipients to market. With a delicate precedent set after the development of the COVID-19 vaccine, we see some significant movement in support of the creation of novel excipients. A key example can be seen with the USA FDA announcing the Novel Excipient Review Pilot Program for the review of novel excipients. This will be used to form the future US development and help reduce some of the barriers to novel excipient introduction.
In the next three to five years, we can expect to see an acceleration in the examination of the composition and purity of excipients.
The future of novel excipients
At Croda Pharma, we recognise the importance and lack of novel excipients and position ourselves to support the industry interest in developing new and innovative ingredients. In addition, excipient purity comes into play, as the level of functionality can, in many cases, be a direct function of the impurity levels.
Dr Sreejit Menon, Research and Technology Manager, Croda Pharma
As the acceleration of examining the purity in excipients heightens, high purity versions of existing excipients can help bridge the gap caused by the lack of novel excipients. Croda Pharma's proprietary purification processes which are used to develop our range of Super Refined™ excipients align with the expanding regulations and investments in innovation seen throughout the industry. Developed to support the most sensitive of formulations, our growing range of Super Refined™ excipients will continue to support our customers and the growing need to formulate with the purest excipients available, both today and in the future.
Innovation is at the forefront of our business, and novel excipients play a crucial part in that.
